|
Our R& D Team:
|
Our Commercial Team:
|
Atheln R & D Team
With over 25 years of experience in biomolecules R&D, Dr. Manzi’s consulting work spans the
areas of recombinant, fusion and transgenic proteins, cell therapies, biosimilars, analytical
method development and validation, CMC, selection and management of CMOs and contract
laboratories, due diligence and writing of expert opinions. As a Consultant, Adriana has led the
CMC efforts for several virtual companies through their first successful IND filing, interacted
with regulators in the US and EU, advised international investors, provided technical opinions to
law firms and participated in global due diligence efforts.
Previously, Dr. Manzi was Sr. Director of Research for Baxter Healthcare Corp., Director of
Analytical Development / Quality Control at Nextran Inc., and Cytel Corporation as well as
Director of the Glycobiology Core Facility at the University of California San Diego (UCSD). Dr.
Manzi has lectured on chemistry and glycobiology as Assistant Professor at UCSD and Adjunct
Professor at San Diego State University. She has also conducted invited workshops at FDA and
NIST and has presented at national and international conferences. She has published 28
research articles and 20 book chapters. She is also member of the Advisory Board of BioProcess
International and a volunteer at the CONNECT Springboard Program.
Dr. Manzi received her B.S. (Chemistry) / M.S. (Industrial Chemistry and Food Sciences), and her
PhD in Organic Chemistry (suma cum laude) from the University of Buenos Aires, Argentina.
She completed her Postdoctoral Research in biochemistry and glycobiology at the UCSD Cancer
Center.
Dr. Jimenez has over 20 years of cancer and vaccine research experience, in academia and at
Vical Inc., augmented by biopharmaceutical product development consulting and business
operations practice with a Regulatory Affairs consulting group, as well as serving as a medical
and small business grant writer.
Dr. Jimenez has operated as a Product Development and Regulatory Affairs consultant to early
stage companies in a variety of therapeutic areas, including cardiovascular, diabetes, oncology,
and blood disorders. She earned a BA in Genetics from UC Berkeley, a PhD in Biology from UC
San Diego, a MBA from San Diego State University, was a postdoctoral fellow at the Salk
Institute, and is US RAC-certified.
Dr. Trown has been has been active in the Pharmaceutical/Biopharmaceutical industry for over
45 years. He held positions of increasing responsibility from researcher to Vice President at
Lederle Laboratories, Hoffmann La Roche, Xoma Corporation, Onyx Pharmaceuticals and
Jennerex Inc. He has extensive experience in the direction of research, preclinical
development, the chemistry, manufacture and control of biopharmaceuticals, and interaction
with FDA and international regulatory agencies.
Drugs for which he had a significant role in their development include alpha-interferon, a 5FU
pro-drug, an immunosuppressive immunoconjugate, an anti-sepsis monoclonal antibody, a
recombinant human protein for trauma/sepsis, a raf kinase inhibitor, selectively-replicating
adenoviruses and vaccinia viruses for the treatment of cancer and a novel chimeric antibody-
like molecule for the treatment of angiogenesis-related diseases.
Over the past 10 years, Dr. Trown has consulted for various biotechnology companies, including
Iconic Therapeutics, BioMarin Pharmaceutical, Onyx Pharmaceuticals, Astex Technology Ltd.,
Gryphon Therapeutics and Cell Genesys on preclinical development of biopharmaceuticals and
low molecular weight drugs.
Dr. Allgren has over 20 years experience in clinical development and regulatory affairs for biotech,
pharma, medical device, diagnostic and stem cell products. She possesses extensive experience
in the design and execution of Phase 1-3 clinical studies, preparation of clinical protocols,
pharmacovigilance / medical monitoring, and the direction of clinical operations, biostatistical and
data management personnel. She is also experienced in FDA interactions, including Pre-IND
Meetings, preparation of clinical and preclinical sections for INDs and NDAs, and preparation/
presentation for FDA Advisory Panels. As Project Team Leader, she has directed product development
activities from preclinical through IND filing, Phase 1-3 clinical development and NDA filing.
Therapeutic areas of endeavor have included cardiovascular disease, oncology, nephrology,
dermatology, pain management, GI, endocrine, infectious disease and CNS disease.
Dr Allgren holds a MD/PhD from Stanford Medical School and an MBA in Health Services Management
from Golden Gate University in San Francisco. She also completed a fellowship in endocrinology at
UCSF. Prior to consulting, she served in senior management roles (such as VP of Clinical Development
and SVP of Development) for several biotech companies, including Ansata, SkyePharma and Scios.
Dr Allgren is US-RAC certified. She also serves as a Domain Expert for the San Diego CONNECT
Springboard business creation and development program.
Former Global Director Regulatory Affairs New Product Development, BioScience, Baxter World
Trade, Christian has over 20 years of experience spanning from International Regulatory Affairs
(EMEA, FDA, EU National Global development) to new product development and QA, ISO
certifications. Christian holds a Master in Bio-Pharmacy, a PhD in Pharmacy and a degree in
Business administration (IAE).
He has been a Resident Biologist in Public Hospitals before moving to the Multinational Health
Care Industry both in the Medical Devices field and in Pharmaceuticals (Institut Merieux, now
Sanofi Aventis; Dow Corning; Boston Scientific; Clintec; Becton Dickinson Baxter. In those
posts, he led the development of numerous products including pharmaceuticals, stents,
implantable devices, and biotherapeutics, including biosimilars. Christian has more than 70
publications and conference presentations, and is a member of numerous Professional
Societies, including DIA, RAPS (former General Secretary, RACS), EUCOMED (former chairman of
the FRG), and APIMCA (former President elect).
Dr. Baughman has more than 20 years experience in Pharmacokinetics and Drug Metabolism,
GLP and GCP compliance, and regulatory submissions. She was the former Executive Director in
Global Research and Development Compliance and Director of Pharmacokinetics and Drug
Metabolism at Amgen. Prior to joining Amgen, Dr. Baughman was Associate Director and
scientist at Genentech Inc. for 9 years working on the development of many protein
therapeutics, including Herceptin, Rituxan, Avastin, Protropin, Nutropin and Pulmozyne.
She has actively been involved with the FDA Critical Path Initiative and the development of
biomarkers to improve the drug development timeline. Dr. Baughman received her PhD in
Chemistry from Rice University.
Sigi has over seventeen years of progressive experience in basic research, regulatory affairs,
clinical research and new business development in both the academic setting and in the
medical device and pharmaceutical industry. As a consultant, she has successfully submitted
ten 510(k)’s, 5 IDE’s, 5INDs, 2 PMA’s, 7 clinical reports, and prepared 12 companies for multiple
determination and negotiation meetings with FDA.
Prior to consulting, Sigi was Vice President of Regulatory Affairs and Quality Assurance at
TheraCardia, a venture-backed startup company developing a paradigm shift emergency
cardiac assist system for treating patients in cardiac arrest. In addition, she held several
management positions at medical device companies including Biosense Webster, a Johnson &
Johnson Company, Smith & Nephew’s Endoscopy Division, Codman, a Johnson & Johnson
company and Johnson & Johnson Orthopedics. Sigi holds a BS in Biology from UCLA and a MBA
from Northeastern University.
Zenaida has over 25 years experience in the pharmaceutical, medical device, IVD, biologics and
nutritional supplements industries, specializing in Quality/Regulatory CGMP, GCP, GLPs, ICH
and ISO compliance. She has been a consultant for over 10 years, assisting companies
domestically and internationally with quality assurance and compliance programs, and the
design and implementation of quality systems from early development to commercial stages.
Prior positions include supervisory and manager roles at GensiaSicor, Inc., Regulatory
Compliance/QA & Professional Services; BioRad Laboratories, Inc., Manufacturing Quality and
Technical Services; J&J Ortho Diagnostics, Manufacturing Lab.; and Central Jersey Blood Bank,
Laboratory. Zenaida has a BS in Biology and advanced degree in Medical Technology. She is
fluent in Spanish.
Atheln Commercial Team
With over 20 years of experience in new product development, strategic planning, and
marketing of pharmaceuticals, biotechnology, and medical devices, Monica has had a unique
career in the life science industry. She has been involved in every aspect of the development
and commercialization process of early and late stage technologies and new therapeutic
applications. In addition, Monica has launched products, medical devices, and new product
indications, both domestically and internationally, and supported both non-dilutive and dilutive
fundraising.
Prior to her consulting career, she held executive and management roles at Allergan, Novo
Nordisk, and a start up company. She has a MBA from Odense University in Denmark, as well
as a BS in Biology and a BA in Economics from the University of California, Irvine.
With over 25 years experience in pharmaceutical sales and marketing, Jane has worked in
numerous acute and chronic therapeutic areas and life style products while at Astra Zeneca,
Roche, and Sanofi. She has been involved in multiple product launches, along with transitioning
products from branded to generic and to OTC, both from a sales and marketing perspective.
Jane has built and managed high performing sales and marketing teams targeting physician
practices, institutional accounts, and managed care. Throughout her career, Jane has been
involved in many in-/out-licensing deals as well as business development activities. Currently,
she is on the board of Medrisk Inc., and TherimuneX, Inc. Jane has a BA in French, BS in
Education from Miami University, and a MBA from Wharton School of the University of
Pennsylvania.
Dr. Pullan has been providing biotech and pharmaceutical companies solutions in identification,
evaluation, valuation, negotiation and strategy for partnering in or out. She has an extensive
deal sheet ranging from company acquisitions to Phase III compounds and from preclinical
candidates to technologies with upfronts ranging from $10K to $100M. Dr. Pullan also served
as President and CEO of Viriome, Inc. and on the board of directors of Paloma Pharmaceuticals,
Inc.
Linda has a Ph.D. in Biochemistry and a B.S. in Chemistry. Linda has more than 20 years of drug
industry experience, beginning in drug discovery at Monsanto/Searle/now Pfizer and
ICI/Zeneca/now AstraZeneca.
She contributed to and led teams that put AstraZeneca’s multi-billion dollar antipsychotic
Seroquel and other molecules into development. Her business development experiences
began with in-licensing technology and early drug candidates in all therapeutic areas at what is
now AstraZeneca, and Dr. Pullan continued as head of oncology and hematology licensing for
Amgen. She then joined Kosan Biosciences as VP of Business Development and experienced all
the tasks of out-licensing and business development in a small company.